Dose effects of human renin in rats transgenic for human angiotensinogen

Hypertension

Volumn 29, Issue 4, 1997, Pages 1031-1038

  Bohlender, Jürgen ^b   Ménard, Joel ^a   Luft, Friedrich C ^c   Ganten, Detlev ^c  

^a INSERM   (France)

^b HUMBOLDT UNIVERSITY   (Germany)

^c NONE

Author keywords

angiotensinogen; gene expression; rats, transgenic; renin

Indexed keywords

ANGIOTENSINOGEN; REMIKIREN; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRINKING; GENE EXPRESSION; HEART RATE; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN RELEASE; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE;

EID: 0342894721     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.4.1031     Document Type: Article

References (35)

1. Erdös EG. Angiotensin I-converting enzyme and the changes in our concept through the years. Hypertension. 1990;16:363-370.
2. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin receptor subtypes. Biochem Biophys Res Commun. 1989;163:284-291.
3. Bohlender J, Ménard J, Wagner J, Luft FC, Ganten D. Human renin-dependent hypertension in rats transgenic for human angiotensinogen. Hypertension. 1996;27(part 2):535-540.
4. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, Ganten U, Kaling M, Bachmann S, Fukamizu A, Mullins JJ, Murakami K. Species specificity of renin kinetics in transgenic rats harbouring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A. 1992;89:7806-7810.
5. Müller DN, Hilgers KF, Bohlender J, Lippoldt A, Wagner J, Fischli W, Ganten D, Mann JFE, Luft FC. Effects of human renin in the vasculature of rats transgenic for human angiotensinogen. Hypertension. 1995;26:272-278.
6. Fischli W, Clozel J-P, El Amrani K, Wostl W, Neidhard W, Stadler H, Branca Q. Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension. 1991;18:22-31.
7. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension. 1985;7(suppl I):I-1-I-7.
8. Genain C, Bouhnik J, Tewksbury D, Corvol P, Ménard J. Characterization of plasma and cerebrospinal fluid human angiotensinogen and des-angiotensin I-angiotensinogen by direct radioimmunoassay. J Clin Endocrinol Metab. 1984;59:478-484.
9. Auffray C, Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem. 1980;107:303-314.
10. Kimura S, Mullins JJ, Bunnemann B, Metzger R, Hilgenfeldt U, Zimmermann F, Jacob H, Fuxe K, Ganten D, Kaling M. High blood pressure in transgenic mice carrying the rat angiotensinogen gene. EMBO J. 1992;11:821-827.
11. Djavidani B, Sander M, Kreutz R, Zeh K, Bader M, Mellon SH, Vecsei P, Peters J, Ganten D. Chronic dexamethasone treatment suppresses hypertension development in the transgenic rat TGR(mREN2)27. J Hypertens. 1995;13:637-645.
12. Costerousse O, Allegrini J, Huang H, Bouhnik J, Alhenc-Gelas F. Regulation of ACE gene expression and plasma levels during rat postnatal development. Am J Physiol. 1994;267:E745-E753.
13. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. I: the production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:349-379.
14. Wilson C, Byrom FB. Renal changes in malignant hypertension: experimental evidence. Lancet. 1939;1:136-139.
15. Volhard F. Über die Pathogenese des roten (essentiellen) arteriellen Hochdrucks und der malignen Sklerose. Schweiz Med Wochenschr. 1948;78:1189-1194.
16. Lenz T, Sealey JE, Maack T, James GD, Heinrikson RL, Marion D, Laragh JH. Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. Am J Physiol. 1991;260: R804-R810.
17. Blackett RB, Depoorter A, Pickering GW, Sellers AL, Wilson GM. Hypertension produced in the rabbit by long continued infusion of renin. Clin Sci. 1950;9:223-245.
18. Lever AF. The fast and slowly developing pressor effects of angiotensin II. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. London, UK: Mosby; 1993:28.1-28.9.
19. Bianchi G, Baldoli E, Lucca R, Barbin P. Pathogenesis of arterial hypertension after constriction of the renal artery leaving the opposite kidney intact both in the anaesthetized and in the conscious dog. Clin Sci. 1972;42:651-664.
20. Bean BL, Brown JJ, Casals-Stenzel J, Fraser R, Lever AF, Millar JA, Morton JJ, Petch B, Riegger AJG, Robertson JIS, Tree M. The relation of arterial pressure and plasma angiotensin II concentration. Circ Res. 1979;44:452-458.
21. Brown AJ, Casals-Stenzel J, Gofford S, Lever AF, Morton JJ. Comparison of fast and slow pressure effects of angiotensin II in the conscious rat. Am J Physiol. 1981;241:H381-H388.
22. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest. 1965;44: 1171-1186.
23. Beevers DG, Brown JJ, Cuesta V, Davies DL, Fraser Lebel M, Lever AF, Morton JJ, Oelkers W, Robertson JIS, Schalekamp MA, Tree M. Inter-relationships between plasma angiotensin II, arterial pressure, aldosterone and exchangeable sodium in normotensive and hypertensive man. J Steroid Biochem. 1975;6:779-785.
24. Cowley AW, DeClue JW. Quantitation of baroreceptor influence on arterial pressure changes seen in primary angiotensin-induced hypertension in dogs. Circ Res. 1976;39:779-787.
25. Zimmermann BG, Sybertz E, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens. 1984;2:581-587.
26. Dowell FJ, Henrion D, Benessiano J, Poitevain P, Levy B. Chronic infusion of low-dose angiotensin II potentiates the adrenergic response in vivo. J Hypertens. 1996;14:177-182.
27. Schottstaedt MF, Sokolow M. The natural history and course of hypertension with papilledema (malignant hypertension). Am Heart J. 1953;65:331-362.
28. Herrmann HC, Morris BJ, Reid IA. Effect of angiotensin II and sodium depletion on angiotensinogen production. Am J Physiol. 1980;238:E145-E149.
29. Khayyall M, MacGregor J, Brown JJ, Lever AF, Robertson JIS. Increase of plasma renin substrate concentration after infusion of angiotensin in the rat. Clin Sci. 1973;44:87-90.
30. Klett C, Bader M, Ganten D, Hackenthal E. Mechanism by which angiotensin II stabilizes messenger RNA for angiotensinogen. Hypertension. 1994;23(suppl I):I-120-I-125.
31. Eggena P, Zhu JH, Clegg K, Barrett JD. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension. 1993;22:496-501.
32. Klett C, Bader M, Schwemmle M, Ganten D, Hackenthal E. Contribution of a 12 kDa protein to angiotensin II-induced stabilization of angiotensinogen mRNA: interaction with the 3′ untranslated mRNA. J Mol Endocrinol. 1995;14:209-226.
33. Clauser E, Bouhnik J, Gonzalez MF, Corvol P, Ménard J. Influence of converting-enzyme inhibition on rat des-angiotensin I-angiotensinogen. Am J Physiol. 1984;246:E129-E133.
34. Arnal JF, Battle T, Rasetti C, Challah M, Costerousse O, Vicaut E, Michel JB, Alhenc-Gelas F. ACE in three tunicae of rat aorta: expression in smooth muscle and effect of renovascular hypertension. Am J Physiol. 1994;267:H1777-H1784.
35. Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H, Schroter V, Belz GG. Hemodynamics, biochemical effects and pharmacokinetics of the renin inhibitor remikifen in healthy human subjects. Clin Pharmacol Ther. 1993;53:585-592.